Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Respiratory syncytial virus (RSV) and influenza typically circulate contemporaneously, meaning co-infections are common. Clinical studies of such co-infection have so far yielded conflicting ...

Respiratory syncytial virus (RSV) is a respiratory infection that has similar symptoms as a cold. But it can be serious for expectant parents who are more at risk for complications from the virus.

At the peak of the respiratory virus season, there could be between 15 and 25 new weekly hospitalizations for every 100,000 people in the US, according to the analysis. Covid-19 will probably ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...